PepGen Inc.
No SEC Form 4 filings for $PEPG in the last 30 days.
See all $PEPG insider activity →PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg t
PepGen Inc. (PEPG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835597 0001835597 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,
Kasraian Kasra (Chief Technical Officer) sold 1,233 shares of PepGen Inc. (PEPG) at $1.41 on 2026-05-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning PEPG (PepGen Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PEPG coverage spans financial news, earnings and corporate actions.
Near-term catalyst is the November readout for the 10 mg/kg FREEDOM2 cohort, following DSMB-approved escalation to 12.5 mg/kg.
The filing is a corporate governance update; it typically has limited direct impact on near-term fundamentals or valuation.
Insider selling is disclosed, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces signal strength.
Despite a 14.3% drop over four weeks, technical indicators suggest possible bullish reversal signals. Fundamental factors are currently neutral, with no major earnings reports or news to confirm a sustained recovery.
The recent buy rating and biological de-risking of PepGen's DM1 program suggest potential upside, especially if higher-dose cohorts demonstrate significant splicing correction. This could lead to a positive price movement.
alphai scores every news story that mentions PEPG with an AI model for sentiment and relevance, and aggregates insider trades from PepGen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
PepGen Inc. (PEPG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pepg-ex99_1.htm EX-99.1 EX-99.1 PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights – DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study, as well as FREEDOM-OLE dose escalation from 5 mg/kg t
4 min readPepGen Inc. (PEPG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001835597 0001835597 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,
2 min readKasraian Kasra (Chief Technical Officer) sold 1,233 shares of PepGen Inc. (PEPG) at $1.41 on 2026-05-21 under a Rule 10b5-1 trading plan.
1 min readThis article discusses the recent 14.3% drop in PepGen (PEPG) stock over the past four weeks. It suggests that despite this downturn, the stock might be poised for a trend reversal. The content will likely delve into technical or fundamental reasons for this potential change in trajectory.
3 min readH.C. Wainwright analyst Ananda Ghosh maintained a Buy rating on PepGen Inc. with a $20.00 price target. Ghosh believes PepGen's DM1 program is de-risked due to stronger underlying biology observed in treated patients, despite a modest average splicing correction skewed by an anomalous patient. The analyst anticipates significant upside from higher-dose cohorts, expecting materially higher splicing correction which could serve as a key value inflection point for the stock.
4 min readPepGen Ltd (NASDAQ:PEPG) shares dropped 44% after-hours following disappointing Phase 2 trial results for its myotonic dystrophy type 1 treatment, PGN-EDODM1. The drug showed an average splicing correction of 7.3% compared to placebo, with an outlier patient significantly impacting the overall mean. Despite the setback, the company plans to report data from a higher dose cohort in late 2026 and has sufficient funding into mid-2027.
3 min readPepGen announced positive safety and splicing results from the 5 mg/kg cohort of its FREEDOM2 trial for PGN-EDODM1, with the drug generally well-tolerated and showing promising trends in splicing correction and vHOT improvement. The company is currently dosing the 10 mg/kg cohort and anticipates data readout in the second half of 2026, with a cash runway extending into the second half of 2027.
3 min readPepGen announced positive data from the 5 mg/kg cohort of its Phase 2 FREEDOM2 MAD study for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). These results support the ongoing evaluation of the 10 mg/kg cohort, with data expected in the latter half of 2026. The company is also scheduled to discuss these developments in an upcoming webcast and recently participated in the MDA2026 conference.
3 min readPepGen Inc. ( NASDAQ: PEPG ) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.
2 min readShares of PepGen Inc. PEPG rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants. PepGen shares jumped 112.4% to $5.65 in the pre-market trading session. Here are some other stocks moving in pre-market ...
3 min read
